Legend: CC = Colorado Convention Center H = Hyatt Regency Denver at Colorado Convention Center
Activity Details
32
Sun, 7/28/2019,
2:00 PM -
3:50 PM
CC-106
Statistical Methods in Dose-Finding Studies — Contributed Papers
Biopharmaceutical Section , International Society for Bayesian Analysis (ISBA), Section on Bayesian Statistical Science
Chair(s): Kevin Gan, GlaxoSmithKline
2:05 PM
Flexible Bayesian Semiparametric Designs for Dose-Finding with Multiple Populations
Jianchang Lin, Takeda Pharmaceuticals ; Mo Li, Yale University; Rachael Liu, Takeda Pharmaceuticals ; Veronica Bunn, Takeda Pharmaceuticals; Hongyu Zhao, Yale
2:20 PM
Design Consideration in Phase 2 Dose Response Trial in the Presence of Possible Non-Monotonicity -- Comparison of Bayesian Emax and NDLM Model
Feng Liu, AstraZeneca ; Stephen Walters, University of Sheffield; Steven Julious, University of Sheffield
2:35 PM
Bayesian Hierarchical EMAX Model for Dose-Response in Early Phase Efficacy Clinical Trials
Byron Gajewski, University of Kansas Medical Center, The University of Kansas Cancer ; Caitlyn Meinzer, Medical University of South Carolina; Scott Berry, Berry Consultants; Gayland L Rockswold, Hennepin County Medical Center; William G Barsan, University of Michigan; Frederick K Korley, University of Michigan; Renee' H Martin, Medical University of South Carolina
2:50 PM
Bayesian Method Based Dose Escalation in Clinical Trials with Combination Therapy
Shanmei Liao, BeiGene ; Theis Lange, University of Copenhagen, section of biostatistics
3:05 PM
A Comparison of the Up-And-Down or Biased Coin Design to the Continual Reassessment Method for Phase I Dose Finding Studies
Robert A. Perera, VCU Department of Biostatistics ; Roy T Sabo, Virginia Commonwealth University; Adam Sima, Virginia Commonwealth University
3:20 PM
Bayesian Dose-Finding Model with Adaptive Time-To-Event Weight Incorporating Cycle Information for Immuno-Oncology Studies
Zhaowei Hua, Alnylam Pharmaceuticals, Inc. ; Yutong Li, University of Illinois at Urbana-Champaign; Ying Yuan, Takeda Pharmaceutical Company Ltd ; Dan Zhao, Takeda Pharmaceutical Company Ltd
3:35 PM
Floor Discussion
